Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.

Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.

Abstract: The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.

Abstract: The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament.

Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The invention provides a phototherapy device that includes a controlled environment defined by a plurality of transparent panels and at least one light emitting diode portion that projects light into the controlled environment.

Abstract: An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.

Abstract: The invention relates to a method and a device for detecting a critical physiological state of a patient, especially for detecting a critical hemodynamic event. A set of values of physiological parameters is measured, including the heart rate and the pulse arrival time. On the basis of these measurements, a risk assessment is performed including the allocation of a representation of the measured set of values as a vector in a vector space to a risk level representing the risk of the occurrence of a critical hemodynamic event.

Abstract: The invention provides anti-MCSP antibodies and methods of using the same.

Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: A computer-implemented method for predicting an onset of an exacerbation in a COPD patient is provided. The method includes measuring physical activity of the patient over a period of time to gather physical activity data; measuring a respiration characteristic of the patient over the period of time to gather respiration data; and executing, on one or more computer processors, one or more computer program modules to detect the onset of the exacerbation based on predetermined criteria, wherein the predetermined criteria comprises a comparison of a change in the respiration data with a change in the physical activity data.

Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The invention relates to a method and apparatus for processing a cyclic physiological signal (30, 40, 52, 53, 54). The method comprises the steps of repeatedly collecting (2) the physiological signal (30, 40, 52, 53, 54) over a time period (31, 32, 33) covering two or more cycles of the cyclic physiological signal (30, 40, 52, 53, 54), wherein a next time period (31, 32, 33) is adjacent to or overlaps with a previous time period (31, 32, 33), extracting values (3, 13) of a set of predefined parameters from the physiological signal (30, 40, 52, 53, 54) within each time period (31, 32, 33) which parameter values characterize the physiological signal (30, 40, 52, 53, 54) within the time period (31, 32, 33), and classifying (4, 14) the physiological signal (30, 40, 52, 53, 54) within each time period (31, 32, 33) based upon the extracted set of predefined parameter values.

Abstract: The invention relates to a method and apparatus for determining a respiration of a subject (305) in which, with a single multi-axial accelerometer (310) positioned on a body of the subject (305), accelerometer signals are generated (101) indicative of the acceleration of the subject (305) along different spatial axes, a vector magnitude signal of the acceleration of the subject (305) along the different spatial axes is calculated (102) from the accelerometer signals, a non-respiratory motion contribution to the acceleration along the different spatial axes is identified (103, 203) from the vector magnitude signal, which non-respiratory motion contribution is not caused by the respiration, and a respiration signal indicative of the respiration of the subject is determined (104, 204) by filtering the non-respiratory motion contribution from at least one of the accelerometer signals.

Abstract: This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical 5 compositions containing said antibodies, and uses thereof.

Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.

Abstract: A method for accelerating a pseudo-random input bit flow (PRBS(T1)), generated at a first relatively low dock frequency (f1), into an identical output bit flow (PRBS(T0)) at a second relatively high dock frequency (f0), comprising: collecting the output bit flow, delaying the collected flow by a predetermined value (?); and combining the delayed flow with the input bit flow.

Abstract: The invention provides a phototherapy device that includes a controlled environment defined by a plurality of transparent panels and at least one light emitting diode portion that projects light into the controlled environment.